William Duke - Pulmatrix Insider

Pulmatrix Inc -- USA Stock  

USD 1.47  0.01  0.68%

CFO, Principal Financial Officer & Principal Accounting Officer

Mr. William E. Duke, Jr., is the Chief Financial Officer of Pulmatrix, Inc. Prior to joining our company, Mr. Duke served as the chief financial officer of Valeritas, a medical technology company, from January 2014 until June 2015 and from July 2011 until January 2014, he served as Valeritass Vice President and Corporationrationrate Controller. At Valeritas, Mr. Duke led the controller relationship, financial planning and analysis, investor relations and information technology functions. Prior to joining Valeritas, Mr. Duke was Senior Director, Finance for Genzyme Corporationrationration, a biopharmaceutical company, from January 2010 to July 2011, where he had oversight responsibility for external reporting to the Securities and Exchange Commission, internal management reporting and worldwide financial consolidation. Prior to Genzyme, he was the Director of Finance and Accounting of Haemonetics Corporationrationration, a medical device company, from May 2008 to January 2010 and held various senior financial roles with consulting services and emerging growth organizations
Age: 42  CFO Since 2015  MBA    
781-357-2333  http://www.pulmatrix.com
Duke holds a B.S. in Accounting from Stonehill College and a M.B.A. with a concentration in Finance from Bentley University and is a Certified Public Accountant.

Management Efficiency

The company has return on total asset (ROA) of (48.95) % which means that it has lost $48.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (154.45) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.9 M in liabilities with Debt to Equity (D/E) ratio of 30.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix Inc has Current Ratio of 1.14 suggesting that it may have difficulties to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix Inc (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 18 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Pattern Recognition Now
   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
Hide  View All  NextLaunch Pattern Recognition
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Pulmatrix Inc to your portfolio

Top Management

Pulmatrix Inc Leadership Team
Terrance McGuire, Director, MBA
Matthew Sherman, Director
Alexander Klibanov, Founder
David Hava, Executive, Ph.D
Akihisa Akao, Director
James Roach, Executive, Ph.D
Michael Higgins, Director, MBA
Steven Gillis, Director
Jean Sung, President
William Duke, CFO, MBA
David Maki, Director
Robert Clarke, CEO, Ph.D
Scott Rocklage, Director, Ph.D
Kurt Graves, Director
Richard Conley, Director, MBA
Mark Iwicki, Chairman, MBA
Amit Munshi, Director, MBA
Gregory French, Director
Hojabr Alimi, Chairman
Prof Edwards, Founder
David JD, Executive

Stock Performance

Pulmatrix Performance Indicators